HCA Healthcare Meets Revenue Forecasts in Q1, But Earnings and Outlook Disappoint
HCA Healthcare, Inc. (NYSE:HCA) reported its first quarter 2026 results on Thursday, delivering a mixed bag of financial metrics that failed to satisfy market expectations despite a top-line figure that came in line with analyst estimates. The stock is trending lower in pre-market trading, reacting to an earnings miss and a cautious reaffirmation of its full-year guidance.
Revenue and Earnings Versus Estimates
The hospital operator posted revenues of $19.109 billion for the three months ended March 31, 2026, marking a 4.3% increase compared to the $18.321 billion reported in the same period last year. While this figure was essentially in line with the consensus estimate of $19.283 billion, the bottom-line results fell short.
HCA reported diluted earnings per share (EPS) of $7.15, up 10.9% from the $6.45 reported in Q1 2025. However, this was below the analyst consensus of $7.23 per share. The company’s adjusted EBITDA came in at $3.802 billion, showing only a 1.9% year-over-year increase.
Key Financial Metrics vs. Estimates:
- Reported Revenue: $19.109 billion (Estimate: $19.283 billion)
- Reported EPS (Non-GAAP): $7.15 (Estimate: $7.23)
- Revenue Growth (YoY): 4.3%
- Net Income: $1.620 billion (+0.6% YoY)
- Adjusted EBITDA: $3.802 billion (+1.9% YoY)
Market Reaction
The market is clearly focused on the earnings shortfall and the muted operational performance. The stock is down approximately 7.2% in pre-market trading, extending a broader decline that has seen HCA shares fall over the past week, two weeks, and month.
The negative price action suggests investors were hoping for a stronger earnings beat or a more aggressive outlook, especially given the challenging volume environment the company described.
Operational Headwinds and Key Highlights from the Press Release
The Q1 report revealed several significant operational challenges that weighed on the results. Management noted that the quarter did not experience a typical seasonal volume increase, primarily due to a sharp decline in respiratory activity.
- Volume Declines: Same facility admissions grew by just 0.9%, while equivalent admissions rose 1.3%. Emergency room visits were essentially flat at 0.3%.
- Respiratory Impact: Respiratory-related admissions were down 42% compared to a strong comparable period in Q1 2025, which had been elevated by a heavy flu and RSV season. Respiratory-related ER visits fell 32%.
- Weather Disruption: A winter storm in January negatively impacted volumes in several of HCA’s markets during the quarter.
- Offsetting Factors: The unfavorable volume impacts were largely offset by the recognition of certain Medicaid supplemental programs that were not initially included in the company’s 2026 guidance.
- Cash Flow & Buybacks: Cash flows from operations improved substantially, rising 22% to $2.014 billion. The company aggressively repurchased 3.157 million shares of its common stock for $1.571 billion during the quarter.
- Dividend: The Board declared a quarterly dividend of $0.78 per share, payable on June 30, 2026.
Outlook and Guidance
Management reaffirmed its full-year 2026 guidance, which was initially issued on January 27, 2026. This decision is likely a key driver of the negative market reaction, as investors may have been looking for an upward revision following the first quarter’s revenue performance.
The company’s guidance incorporates expectations for “volume growth coupled with an anticipated mostly stable operating environment,” but it explicitly excludes the impact of future state Medicaid approvals. It also factors in potential headwinds from the expiration of enhanced premium tax credits and the impact of trade policies, including tariffs.
When compared to analyst estimates for the full year, the lack of a raised bar is notable. The current consensus calls for full-year 2026 sales of $79.46 billion and EPS of $30.66. For the upcoming Q2 2026, analysts forecast sales of $19.52 billion and EPS of $7.54. HCA’s decision to hold its guidance steady suggests management sees significant uncertainty in the near term.
Analyst Views
The combination of a modest EPS miss, tepid volume growth, and a reaffirmed—rather than raised—outlook will likely lead to a flurry of analyst revisions. While the company’s strong cash flow generation and aggressive capital return program (buybacks and dividends) remain positive structural features, the fundamental operating picture appears to be in a holding pattern. The lack of a typical seasonal volume rebound, particularly in respiratory cases, is a temporary headwind, but the uncertainty surrounding payer mix, health insurance exchange dynamics, and broader economic conditions is clearly weighing on the outlook.
To see more historical earnings data and future projections for HCA, please visit the earnings and analyst forecast pages:
Disclaimer: This article is for informational purposes only and does not constitute investment advice. You should consult with a qualified financial professional before making any investment decisions.